Consolidation therapy in ovarian cancer: a clinical update. Review uri icon


MeSH Major

  • Antineoplastic Agents
  • Carcinoma
  • Ovarian Neoplasms


  • As treatment options move beyond classic chemotherapy to novel hormones, immune interventions, and biologic agents, the consolidation strategy is regaining interest. This is particularly attractive in that many of these agents have stable disease as best outcome, and this is most appropriate to evaluate in patients with minimal volume disease. A consideration of toxicity is paramount, and any strategy to be considered in an otherwise asymptomatic patient in remission must be well tolerated. In addition, patients in second or third complete remission are also being considered as an appropriate group in which to evaluate new agents. Numerous other phase 2 trials with novel agents not considered here are underway, and it is to be hoped that some will emerge as contenders for randomized trials. Participation in these trials remains a priority for patients who otherwise must pursue a difficult watch-and-wait strategy.

publication date

  • December 2009



  • Review



  • eng

PubMed ID

  • 19955912

Additional Document Info

start page

  • S35

end page

  • 9


  • 19 Suppl 2